Non-invasive MRD Assessment in Multiple Myeloma

Launched by RAJSHEKHAR CHAKRABORTY, MD · Nov 15, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to check for minimal residual disease (MRD) in patients with multiple myeloma, a type of blood cancer. The researchers want to see if they can use a simple blood test and a special kind of imaging called whole body MRI instead of the more invasive method of taking samples from the bone marrow. The goal is to find out if these non-invasive methods are just as effective in detecting any remaining cancer cells after treatment, which could help many patients avoid painful procedures in the future.

To participate in this study, you need to be at least 18 years old and have either recently been diagnosed with multiple myeloma or have received some treatment in the past. You should also be planning to start a new treatment and be expected to live for more than a year. However, there are some conditions that may prevent you from joining, such as difficulty with MRI procedures or certain medical devices like pacemakers. If you choose to participate, you will undergo a blood draw and the MRI scan, which are designed to help researchers learn more about the effectiveness of these new assessment methods.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults age ≥18 years
• • Patients with newly diagnosed multiple myeloma
• • Patients with previously treated multiple myeloma with a maximum of two prior lines of therapy
• • Expected life expectancy of greater than one year and intention to start a new line of treatment
• Exclusion Criteria:
• • Patients without cognitive capacity to give informed consent for participation
• * Patients with contraindications to MRI, which include the following:
• • Claustrophobia, which, at investigator's discretion, would prohibit patient from undergoing whole body diffusion-weighted magnetic resonance imaging (WB-DWI)
• • Pacemaker
• • Metallic implants, which would prohibit patient from undergoing MRI All subjects will be screened for any contraindication to MRI as per their guidelines at the time of patient enrollment.
• • Patients must not receive granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) injection within 1 week prior to WB-DWI.
• • Patients must not have been initiated on treatment prior to baseline disease assessment by bone marrow aspiration/biopsy and/or WB-DWI Up to 160 mg of dexamethasone (or equivalent) and/or 1 dose of bortezomib (+/- Cyclophosphamide-Dexamethasone) is allowed prior to disease assessment by bone marrow aspiration and WB-DWI.